PERRIGO FIRST-QUARTER SALES INCREASE 6% TO $182.7 MIL.
This article was originally published in The Tan Sheet
Executive Summary
PERRIGO FIRST-QUARTER SALES INCREASE 6% TO $182.7 MIL. led by gains in analgesics, vitamins, cough and cold remedies and antacids, the company said in an Oct. 28 release. The company said it achieved "moderate" sales growth for the three-month period ended Sept. 30 despite a "later start to the cough and cold season this year and a soft market in analgesics."
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
People In Brief
Perrigo promotes in pricing, planning
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: